These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 27506293)

  • 1. Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing.
    Didiot MC; Hall LM; Coles AH; Haraszti RA; Godinho BM; Chase K; Sapp E; Ly S; Alterman JF; Hassler MR; Echeverria D; Raj L; Morrissey DV; DiFiglia M; Aronin N; Khvorova A
    Mol Ther; 2016 Oct; 24(10):1836-1847. PubMed ID: 27506293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loading of Extracellular Vesicles with Hydrophobically Modified siRNAs.
    Didiot MC; Haraszti RA; Aronin N; Khvorova A
    Methods Mol Biol; 2018; 1740():199-214. PubMed ID: 29388146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier.
    Godinho BMDC; Henninger N; Bouley J; Alterman JF; Haraszti RA; Gilbert JW; Sapp E; Coles AH; Biscans A; Nikan M; Echeverria D; DiFiglia M; Aronin N; Khvorova A
    Mol Ther; 2018 Nov; 26(11):2580-2591. PubMed ID: 30143435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles.
    Haraszti RA; Miller R; Didiot MC; Biscans A; Alterman JF; Hassler MR; Roux L; Echeverria D; Sapp E; DiFiglia M; Aronin N; Khvorova A
    Mol Ther; 2018 Aug; 26(8):1973-1982. PubMed ID: 29937418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs.
    Zhang L; Wu T; Shan Y; Li G; Ni X; Chen X; Hu X; Lin L; Li Y; Guan Y; Gao J; Chen D; Zhang Y; Pei Z; Chen X
    Brain; 2021 Dec; 144(11):3421-3435. PubMed ID: 34918046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA Conjugate in Mouse Brain.
    Nikan M; Osborn MF; Coles AH; Biscans A; Godinho BMDC; Haraszti RA; Sapp E; Echeverria D; DiFiglia M; Aronin N; Khvorova A
    Bioconjug Chem; 2017 Jun; 28(6):1758-1766. PubMed ID: 28462988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain.
    Alterman JF; Hall LM; Coles AH; Hassler MR; Didiot MC; Chase K; Abraham J; Sottosanti E; Johnson E; Sapp E; Osborn MF; Difiglia M; Aronin N; Khvorova A
    Mol Ther Nucleic Acids; 2015 Dec; 4(12):e266. PubMed ID: 26623938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model.
    Mendonça MCP; Cronin MF; Cryan JF; O'Driscoll CM
    Eur J Pharm Biopharm; 2021 Dec; 169():309-318. PubMed ID: 34793942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system.
    Alterman JF; Godinho BMDC; Hassler MR; Ferguson CM; Echeverria D; Sapp E; Haraszti RA; Coles AH; Conroy F; Miller R; Roux L; Yan P; Knox EG; Turanov AA; King RM; Gernoux G; Mueller C; Gray-Edwards HL; Moser RP; Bishop NC; Jaber SM; Gounis MJ; Sena-Esteves M; Pai AA; DiFiglia M; Aronin N; Khvorova A
    Nat Biotechnol; 2019 Aug; 37(8):884-894. PubMed ID: 31375812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs
    Allen S; O'Reilly D; Miller R; Sapp E; Summers A; Paquette J; Echeverria Moreno D; Bramato B; McHugh N; Yamada K; Aronin N; DiFiglia M; Khvorova A
    Nucleic Acid Ther; 2024 Aug; 34(4):164-172. PubMed ID: 39023561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
    Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
    J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-mediated delivery of siRNA in vitro and in vivo.
    El-Andaloussi S; Lee Y; Lakhal-Littleton S; Li J; Seow Y; Gardiner C; Alvarez-Erviti L; Sargent IL; Wood MJ
    Nat Protoc; 2012 Dec; 7(12):2112-26. PubMed ID: 23154783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant Huntingtin Inhibits αB-Crystallin Expression and Impairs Exosome Secretion from Astrocytes.
    Hong Y; Zhao T; Li XJ; Li S
    J Neurosci; 2017 Sep; 37(39):9550-9563. PubMed ID: 28893927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits.
    DiFiglia M; Sena-Esteves M; Chase K; Sapp E; Pfister E; Sass M; Yoder J; Reeves P; Pandey RK; Rajeev KG; Manoharan M; Sah DW; Zamore PD; Aronin N
    Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17204-9. PubMed ID: 17940007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A High-throughput Assay for mRNA Silencing in Primary Cortical Neurons
    Alterman JF; Coles AH; Hall LM; Aronin N; Khvorova A; Didiot MC
    Bio Protoc; 2017 Aug; 7(16):. PubMed ID: 28966945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.
    Conroy F; Miller R; Alterman JF; Hassler MR; Echeverria D; Godinho BMDC; Knox EG; Sapp E; Sousa J; Yamada K; Mahmood F; Boudi A; Kegel-Gleason K; DiFiglia M; Aronin N; Khvorova A; Pfister EL
    Nat Commun; 2022 Oct; 13(1):5802. PubMed ID: 36192390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
    Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
    Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse.
    Liu Y; Li D; Liu Z; Zhou Y; Chu D; Li X; Jiang X; Hou D; Chen X; Chen Y; Yang Z; Jin L; Jiang W; Tian C; Zhou G; Zen K; Zhang J; Zhang Y; Li J; Zhang CY
    Sci Rep; 2015 Dec; 5():17543. PubMed ID: 26633001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Roles of Exosomes in Huntington's Disease.
    Ananbeh H; Vodicka P; Kupcova Skalnikova H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.